1.
Michihiro Ishida, Shigeki Sekine, Takeo Fukagawa, Masaki Ohashi, Shinji Morita,
Hirokazu Taniguchi, Hitoshi Katai, Hitoshi Tsuda, Ryoji Kushima. Neuroendocrine
carcinoma of the stomach: morphologic and immunohistochemical characteristics and
prognosis. Am. J. Surg. Pathol. 2013; 37; 949–959.
2.
Takeshi Kubota, Shigekazu Ohyama, Naoki Hiki, Souya Nunobe, Noriko Yamamoto,
Toshiharu Yamaguchi. Endocrine carcinoma of the stomach: clinicopathological analysis
of 27 surgically treated cases in a single institute. Gastric Cancer 2012; 15; 323–330.
3.
La Rosa S, Rindi G, Solcia E, Tang LH. Gastric neuroendocrine neoplasms. In WHO
Classification of Tumours Editorial Board eds. World Health Organization classification of
tumours. Digestive system tumours, 5th edn. Lyon: IARC Press, 2019; 104–109.
4.
Garcia-Carbonero R, Sorbye H, Baudin E, Raymond E, Wiedenmann B, Niederle B,
Sedlackova E, Toumpanakis C, Anlauf M, Cwikla J.B, Caplin M, O''Toole D, Perren A, all
other Vienna Consensus Conference participants. ENETS consensus guidelines for highgrade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas.
Neuroendocrinology 2016; 103; 186–194.
5.
Olatunji B Alese, Renjian Jiang, Walid Shaib, Christina Wu, Mehmet Akce, Madhusmita
Behera, Bassel F El-Rayes. High-grade gastrointestinal neuroendocrine carcinoma
management and outcomes: a national cancer database study. Oncologist 2019; 24; 911–
920.
6.
Gregory P Kalemkerian, Billy W Loo, Wallace Akerley, Albert Attia, Michael Bassetti,
Yanis Boumber, Roy Decker, M Chris Dobelbower, Afshin Dowlati, Robert J Downey,
Charles Florsheim, Apar Kishor P Ganti, John C Grecula, Matthew A Gubens, Christine L
90
Hann, James A Hayman, Rebecca Suk Heist, Marianna Koczywas, Robert E Merritt, Nisha
Mohindra, Julian Molina, Cesar A Moran, Daniel Morgensztern, Saraswati Pokharel, David
C Portnoy, Deborah Rhodes, Chad Rusthoven, Jacob Sands, Rafael Santana-Davila,
Charles C Williams, Karin G Hoffmann, Miranda Hughes. NCCN guidelines insights: small
cell lung cancer, Version 2.2018. J. Natl. Compr. Canc. Netw. 2018; 16; 1171–1182.
7.
Yung-Jue Bang, Eric Van Cutsem, Andrea Feyereislova, Hyun C Chung, Lin Shen, Akira
Sawaki, Florian Lordick, Atsushi Ohtsu, Yasushi Omuro, Taroh Satoh, Giuseppe Aprile,
Evgeny Kulikov, Julie Hill, Michaela Lehle, Josef Rüschoff, Yoon-Koo Kang, ToGA Trial
Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone
for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer
(ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376; 687–697.
8.
Michihiro Ishida, Shigeki Sekine, Hirokazu Taniguchi, Takeo Fukagawa, Hitoshi Katai,
Ryoji Kushima. Consistent absence of HER2 expression, regardless of HER2 amplification
status, in neuroendocrine carcinomas of the stomach. Histopathology 2014; 64; 1027–1031.
9.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology.
Esophageal and esophagogastric junction cancers. Version 2.2018. Available at:
www.nccn.org/professionals/physician_gls/default.aspx (accessed 30 April 2020).
10.
Jordan A Roberts, Raul S Gonzalez, Satya Das, Jordan Berlin, Chanjuan Shi. Expression of
PD-1 and PD-L1 in poorly differentiated neuroendocrine carcinomas of the digestive
system: a potential target for anti-PD-1/PD-L1 therapy. Hum. Pathol. 2017; 70; 49–54.
11.
Seung Tae Kim, Sang Yun Ha, Sujin Lee, Soomin Ahn, Jeeyun Lee, Se Hoon Park, Joon
Oh Park, Ho Yeong Lim, Won Ki Kang, Kyoung-Mee Kim, Young Suk Park. The impact
of PD-L1 expression in patients with metastatic GEP-NETs. J. Cancer 2016; 7; 484–489.
12.
Min-Wei Yang, Xue-Liang Fu, Yong-Sheng Jiang, Xiao-Jing Chen, Ling-Ye Tao, Jian-Yu
91
Yang, Yan-Miao Huo, Wei Liu, Jun-Feng Zhang, Pei-Feng Liu, Qiang Liu, Rong Hua, ZhiGang Zhang, Yong-Wei Sun, and De-Jun Liu. Clinical significance of programmed death
1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas. World J.
Gastroenterol. 2019; 25; 1684–1696.
13.
Edward B Garon, Naiyer A Rizvi, Rina Hui, Natasha Leighl, Ani S Balmanoukian, Joseph
Paul Eder, Amita Patnaik, Charu Aggarwal, Matthew Gubens, Leora Horn, Enric Carcereny,
Myung-Ju Ahn, Enriqueta Felip, Jong-Seok Lee, Matthew D Hellmann, Omid Hamid,
Jonathan W Goldman, Jean-Charles Soria, Marisa Dolled-Filhart, Ruth Z Rutledge, Jin
Zhang, Jared K Lunceford, Reshma Rangwala, Gregory M Lubiniecki, Charlotte Roach,
Kenneth Emancipator, Leena Gandhi, KEYNOTE-001 Investigators. Pembrolizumab for
the treatment of non-small-cell lung cancer. N. Engl. J. Med. 2015; 372; 2018–2028.
14.
Roy S. Herbst, Jean-Charles Soria, Marcin Kowanetz, Gregg D. Fine, Omid Hamid,
Michael S. Gordon, Jeffery A. Sosman, David F. McDermott, John D. Powderly, Scott N.
Gettinger, Holbrook E. K. Kohrt, Leora Horn, Donald P. Lawrence, Sandra Rost, Maya
Leabman, Yuanyuan Xiao, Ahmad Mokatrin, Hartmut Koeppen, Priti S. Hegde, Ira
Mellman, Daniel S. Chen & F. Stephen Hodi. Predictive correlates of response to the antiPD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515; 563–567.
15.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi,
Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe, Mary O'Brien, Suman
Rao, Katsuyuki Hotta, Melanie A Leiby, Gregory M Lubiniecki, Yue Shentu, Reshma
Rangwala, Julie R Brahmer, KEYNOTE-024 Investigators. Pembrolizumab versus
chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 2016; 375;
1823–1833.
16.
Kohei Shitara, Mustafa Özgüroğlu, Yung-Jue Bang, Maria Di Bartolomeo, Mario Mandalà,
92
Min-Hee Ryu, Lorenzo Fornaro, Tomasz Olesiński, Christian Caglevic, Hyun C Chung,
Kei Muro, Eray Goekkurt, Wasat Mansoor, Raymond S McDermott, Einat ShachamShmueli, Xinqun Chen, Carlos Mayo , S Peter Kang, Atsushi Ohtsu, Charles S Fuchs,
KEYNOTE-061 investigators. Pembrolizumab versus paclitaxel for previously treated,
advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised,
open-label, controlled, phase 3 trial. Lancet 2018; 392; 123–133.
17.
Karina Kulangara, Nancy Zhang, Ellie Corigliano, Lindsay Guerrero, Stephanie Waldroup,
Dipeshkumar Jaiswal, Malinka Jansson Ms, Supriya Shah, Debra Hanks, Jiangdian Wang,
Jared Lunceford, Mary J Savage, Jonathan Juco, Kenneth Emancipator. Clinical utility of
the combined positive score for programmed death ligand-1 expression and the approval of
pembrolizumab for treatment of gastric cancer. Arch. Pathol. Lab. Med. 2019; 143; 330–
337.
18.
Yamashita K, Iwatsuki M, Harada K, Eto K, Hiyoshi Y, Ishimoto T, Nagai Y, Iwagami S,
Miyamoto Y, Yoshida N, Komohara Y, Ajani JA, Baba H. Prognostic impacts of the
combined positive score and the tumor proportion score for programmed death ligand-1
expression by double immunohistochemical staining in patients with advanced gastric
cancer. Gastric Cancer. 2020 Jan; 23(1); 95-104.
19.
Lola Fashoyin-Aje, Martha Donoghue, Huanyu Chen, Kun He, Janaki Veeraraghavan,
Kirsten B Goldberg, Patricia Keegan, Amy E McKee, Richard Pazdur. FDA approval
summary: pembrolizumab for recurrent locally advanced or metastatic gastric or
gastroesophageal junction adenocarcinoma expressing PD-L1. Oncologist. 2019; 24; 103–
109.
20.
X C Wang, J Q Zhang, Y Q Shen, F Q Miao, W Xie. Loss of heterozygosity at 6p21.3
underlying HLA class I downregulation in gastric cancer. J Exp Clin Cancer Res. 2006; 25;
93
115-9.
21.
Sumiya Ishigami, Takaaki Arigami, Yoshikazu Uenosono, Masataka Matsumoto, Hiroshi
Okumura, Yasuto Uchikado, Yoshiaki Kita, Yuka Nishizono, Kosei Maemura, Yuko Kijima,
Akihiro Nakajo, Tetsuhiro Owaki, Shinichi Ueno, Shuichi Hokita, Shoji Natsugoe.
Cancerous HLA class I expression and regulatory T cell infiltration in gastric cancer.
Cancer Immunol Immunother. 2012; 61; 1663-9.
22.
Raghav Sundar, Sun Young Rha, Hiroki Yamaue, Masahiro Katsuda, Koji Kono, Hyo Song
Kim, Chan Kim, Kousaku Mimura, Ley-Fang Kua, Wei Peng Yong. A phase I/Ib study of
OTSGC-A24 combined peptide vaccine in advanced gastric cancer. BMC Cancer. 2018;
18; 332.
23.
Raghav Sundar, Chee Cheng Ean, Yong Wei Peng. Preliminary results of the daVinci study:
OTSGC-A24 vaccine + nivolumab in metastatic gastric cancer (Phase I study preliminary
report. National Univ. Health System, Singapore). Gastric Cancer. 2020; 92; 315.
24.
Paola Minetto, Fabio Guolo, Silvia Pesce, Marco Greppi, Valentina Obino, Elisa Ferretti,
Simona Sivori, Carlo Genova, Roberto Massimo Lemoli, Emanuela Marcenaro. Harnessing
NK cells for cancer treatment. Front Immunol. 2019; 10; 2836.
25.
Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based
immunotherapy. Lancet Oncol. 2016; 17; e542-51.
26.
Katsuhiko Nosho, Yoshifumi Baba, Noriko Tanaka, Kaori Shima, Marika Hayashi, Jeffrey
A Meyerhardt, Edward Giovannucci, Glenn Dranoff, Charles S Fuchs, Shuji Ogino.
Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis:
cohort study and literature review. J Pathol. 2010; 222; 350-366.
27.
Michele W L Teng, Shin Foong Ngiow, Antoni Ribas, Mark J Smyth. Classifying cancers
based on T-cell infiltration and PD-L1. Can Res. 2015; 75; 2139-45.
94
28.
Mark J Smyth, Shin Foong Ngiow, Antoni Ribas, Michele W L Teng. Combination cancer
immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol. 2016; 13;
143-158.
29.
Nora Sahnane, Daniela Furlan, Matilde Monti, Chiara Romualdi, Alessandro Vanoli,
Emanuela Vicari, Enrico Solcia, Carlo Capella, Fausto Sessa, Stefano La Rosa.
Microsatellite
unstable
gastrointestinal
neuroendocrine
carcinomas:
new
clinicopathologic entity. Endocr. Relat. Cancer 2015; 22; 35–45.
30.
Yamamoto H, Imai K. Microsatellite instability: an update. Arch Toxicol. 2015 Jun; 89(6);
899-921.
31.
The Cancer Genome Atlas Research Network. Comprehensive molecular characterization
of gastric adenocarcinoma. Nature. 2014; 513; 202–209.
32.
Sabry D, Ahmed R, Abdalla S, Fathy W, Eldemery A, Elamir A. Braf, Kras and Helicobacter
pylori epigenetic changes-associated chronic gastritis in Egyptian patients with and without
gastric cancer. World J Microbiol Biotechnol. 2016 Jun; 32(6); 92.
33.
Oliveira C, Pinto M, Duval A, Brennetot C, Domingo E, Espín E, Armengol M, Yamamoto
H, Hamelin R, Seruca R, Schwartz S Jr. BRAF mutations characterize colon but not gastric
cancer with mismatch repair deficiency. Oncogene. 2003 Dec 11; 22(57); 9192-6.
34.
Ishida S, Akita M, Fujikura K, Komatsu M, Sawada R, Matsumoto H, Saegusa J, Itoh T,
Kakeji Y, Zen Y. Neuroendocrine carcinoma and mixed neuroendocrine-nonneuroendocrine neoplasm of the stomach: a clinicopathological and exome sequencing
study. Hum Pathol. 2021 Jan 20; 110; 1-10.
35.
Chen J, Wang A, Ji K, Bu Z, Ji J. Comparison of overall survival of gastric neoplasms
containing neuroendocrine carcinoma components with gastric adenocarcinoma: a
propensity score matching study. BMC Cancer. 2020 Aug 18; 20(1); 777.
95
36.
Makuuchi R, Terashima M, Kusuhara M, Nakajima T, Serizawa M, Hatakeyama K,
Ohshima K, Urakami K, Yamaguchi K. Comprehensive analysis of gene mutation and
expression profiles in neuroendocrine carcinomas of the stomach. Biomed Res. 2017; 38(1);
19-27.
37.
Wang F, Liu DB, Zhao Q, Chen G, Liu XM, Wang YN, Su H, Qin YR, He YF, Zou QF, Liu
YH, Lin YE, Liu ZX, Bei JX, Xu RH. The genomic landscape of small cell carcinoma of
the esophagus. Cell Res. 2018 Jul; 28(7); 771-774.
38.
Ragavan M, Das M. Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the
Era of Immunotherapy. Curr Treat Options Oncol. 2020 Jun 29; 21(8); 64.
39.
Lydia Meder, Katharina König, Luka Ozretić, Anne M Schultheis, Frank Ueckeroth,
Carsten P Ade , Kerstin Albus, Diana Boehm, Ursula Rommerscheidt-Fuss, Alexandra
Florin, Theresa Buhl, Wolfgang Hartmann, Jürgen Wolf, Sabine Merkelbach-Bruse, Martin
Eilers, Sven Perner, Lukas C Heukamp, Reinhard Buettner. NOTCH, ASCL1, p53 and RB
alterations define an alternative pathway driving neuroendocrine and small cell lung
carcinomas. Int. J. Cancer 2016; 138; 927–938.
40.
Hsueh-Li Tan, Akshay Sood, Hameed A Rahimi, Wenle Wang, Nilesh Gupta, Jessica Hicks,
Stacy Mosier, Christopher D Gocke, Jonathan I Epstein, George J Netto, Wennuan Liu,
William B Isaacs, Angelo M De Marzo, Tamara L Lotan. Rb loss is characteristic of
prostatic small cell neuroendocrine carcinoma. Clin. Cancer Res. 2014; 20; 890–903.
41.
Daniel M Girardi, Andrea C B Silva, Juliana Florinda M Rêgo, Renata A Coudry, Rachel P
Riechelmann. Unraveling molecular pathways of poorly differentiated neuroendocrine
carcinomas of the gastroenteropancreatic system: a systematic review. Cancer Treat. Rev.
2017; 56; 28–35.
42.
Koichiro Fujimasa, Nobuyuki Ohike, Tomoko Norose, Tomohide Isobe, Kazuo Kikuchi,
96
Koji Otsuka, Masahiko Murakami, Masafumi Takimoto. Frequent and specific involvement
of changes of the p16-RB pathway in esophageal neuroendocrine carcinoma. Anticancer
Res. 2019; 39; 1927–1934.
43.
Angela N Bartley, Mary Kay Washington, Carol Colasacco, Christina B Ventura, Nofisat
Ismaila, Al B Benson 3rd, Alfredo Carrato, Margaret L Gulley, Dhanpat Jain, Sanjay Kakar,
Helen J Mackay, Catherine Streutker, Laura Tang, Megan Troxell, Jaffer A Ajani. HER2
testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from
the College of American Pathologists, American Society for Clinical Pathology, and the
American Society of Clinical Oncology. J. Clin. Oncol. 2017; 35; 446–464.
44.
Ishigami S, Natsugoe S, Nakajo A, Arigami T, Kitazono M, Okumura H, Matsumoto M,
Uchikado Y, Setoyama T, Sasaki K, Aikou T. HLA-class I expression in gastric cancer. J
Surg Oncol. 2008; 97; 605-8.
45.
Zhang X, Lin A, Zhang JG, Bao WG, Xu DP, Ruan YY, Yan WH. Alteration of HLA-F and
HLA I antigen expression in the tumor is associated with survival in patients with
esophageal squamous cell carcinoma. Int J Cancer. 2013; 132; 82-9.
46.
W M Grady, A Rajput, J D Lutterbaugh, S D Markowitz. Detection of aberrantly methylated
hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer.
Cancer Res. 2001; 61; 900–2.
47.
Chung-Liang Ho, Robert J Kurman, Reiko Dehari, Tian-Li Wang, Ie-Ming Shih. Mutations
of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer
Res. 2004; 64; 6915–8.
48.
Shona Hendry, Roberto Salgado, Thomas Gevaert, Prudence A Russell, Tom John, Bibhusal
Thapa, Michael Christie, Koen van de Vijver, M V Estrada, Paula I Gonzalez-Ericsson,
Melinda Sanders, Benjamin Solomon, Cinzia Solinas, Gert G G M Van den Eynden, Yves
97
Allory, Matthias Preusser, Johannes Hainfellner, Giancarlo Pruneri, Andrea Vingiani,
Sandra Demaria, Fraser Symmans, Paolo Nuciforo, Laura Comerma, E A Thompson, Sunil
Lakhani, Seong-Rim Kim, Stuart Schnitt, Cecile Colpaert, Christos Sotiriou, Stefan J
Scherer, Michail Ignatiadis, Sunil Badve, Robert H Pierce, Giuseppe Viale, Nicolas Sirtaine,
Frederique Penault-Llorca, Tomohagu Sugie, Susan Fineberg, Soonmyung Paik, Ashok
Srinivasan, Andrea Richardson, Yihong Wang, Ewa Chmielik, Jane Brock, Douglas B
Johnson, Justin Balko, Stephan Wienert, Veerle Bossuyt, Stefan Michiels, Nils Ternes,
Nicole Burchardi, Stephen J Luen, Peter Savas, Frederick Klauschen, Peter H Watson, Brad
H Nelson, Carmen Criscitiello, Sandra O'Toole, Denis Larsimont, Roland de Wind,
Giuseppe Curigliano, Fabrice André, Magali Lacroix-Triki, Mark van de Vijver, Federico
Rojo, Giuseppe Floris, Shahinaz Bedri, Joseph Sparano, David Rimm, Torsten Nielsen,
Zuzana Kos, Stephen Hewitt, Baljit Singh, Gelareh Farshid, Sibylle Loibl, Kimberly H
Allison, Nadine Tung, Sylvia Adams, Karen Willard-Gallo, Hugo M Horlings, Leena
Gandhi, Andre Moreira, Fred Hirsch, Maria V Dieci, Maria Urbanowicz, Iva Brcic,
Konstanty Korski, Fabien Gaire, Hartmut Koeppen, Amy Lo, Jennifer Giltnane, Marlon C
Rebelatto, Keith E Steele, Jiping Zha, Kenneth Emancipator, Jonathan W Juco, Carsten
Denkert, Jorge Reis-Filho, Sherene Loi, Stephen B Fox. Assessing tumor-infiltrating
lymphocytes in solid tumors: a practical review for pathologists and proposal for a
standardized method from the International Immunooncology Biomarkers Working Group:
Part 1: Assessing the host immune response, TILs in invasive breast carcinoma and ductal
carcinoma in situ, metastatic tumor deposits and areas for further research. Adv. Anat.
Pathol. 2017; 24; 235–251.
49.
Shona Hendry, Roberto Salgado, Thomas Gevaert, Prudence A Russell, Tom John, Bibhusal
Thapa, Michael Christie, Koen van de Vijver, M V Estrada, Paula I Gonzalez-Ericsson,
98
Melinda Sanders, Benjamin Solomon, Cinzia Solinas, Gert G G M Van den Eynden, Yves
Allory, Matthias Preusser, Johannes Hainfellner, Giancarlo Pruneri, Andrea Vingiani,
Sandra Demaria, Fraser Symmans, Paolo Nuciforo, Laura Comerma, E A Thompson, Sunil
Lakhani, Seong-Rim Kim, Stuart Schnitt, Cecile Colpaert, Christos Sotiriou, Stefan J
Scherer, Michail Ignatiadis, Sunil Badve, Robert H Pierce, Giuseppe Viale, Nicolas Sirtaine,
Frederique Penault-Llorca, Tomohagu Sugie, Susan Fineberg, Soonmyung Paik, Ashok
Srinivasan, Andrea Richardson, Yihong Wang, Ewa Chmielik, Jane Brock, Douglas B
Johnson, Justin Balko, Stephan Wienert, Veerle Bossuyt, Stefan Michiels, Nils Ternes,
Nicole Burchardi, Stephen J Luen, Peter Savas, Frederick Klauschen, Peter H Watson, Brad
H Nelson, Carmen Criscitiello, Sandra O'Toole, Denis Larsimont, Roland de Wind,
Giuseppe Curigliano, Fabrice André, Magali Lacroix-Triki, Mark van de Vijver, Federico
Rojo, Giuseppe Floris, Shahinaz Bedri, Joseph Sparano, David Rimm, Torsten Nielsen,
Zuzana Kos, Stephen Hewitt, Baljit Singh, Gelareh Farshid, Sibylle Loibl, Kimberly H
Allison, Nadine Tung, Sylvia Adams, Karen Willard-Gallo, Hugo M Horlings, Leena
Gandhi, Andre Moreira, Fred Hirsch, Maria V Dieci, Maria Urbanowicz, Iva Brcic,
Konstanty Korski, Fabien Gaire, Hartmut Koeppen, Amy Lo, Jennifer Giltnane, Marlon C
Rebelatto, Keith E Steele, Jiping Zha, Kenneth Emancipator, Jonathan W Juco, Carsten
Denkert, Jorge Reis-Filho, Sherene Loi, Stephen B Fox. Assessing tumor-infiltrating
lymphocytes in solid tumors: a practical review for pathologists and proposal for a
standardized method from the International Immunooncology Biomarkers Working Group:
Part 2: TILs in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma
and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the
head and neck, genitourinary carcinomas, and primary brain tumors. Adv. Anat. Pathol.
2017; 24; 311–335.
99
50.
Yujun Park, Jiwon Koh, Hee Young Na, Yoonjin Kwak, Keun-Wook Lee, Sang-Hoon Ahn,
Do Joong Park, Hyung-Ho Kim, Hye Seung Lee. PD-L1 testing in gastric cancer by the
combined positive score of the 22C3 PharmDx and SP263 assay with clinically relevant
cut-offs. Cancer Res. Treat. 2020; 52; 661–670.
51.
Simona Gurzu, Annamaria Fetyko, Tivadar Bara, Laura Banias, Vlad Olimpiu Butiurca,
Tivadar Bara Jr, Vlad Tudorache, Ioan Jung. Gastrointestinal mixed adenoneuroendocrine
carcinoma (MANEC): an immunohistochemistry study of 13 microsatellite stable cases.
Pathol. Res. Pract. 2019; 215; 152697.
52.
Toru Masuzawa, Yoshiyuki Fujiwara, Kaoru Okada, Ayumu Nakamura, Shuji Takiguchi,
Kiyokazu Nakajima, Hiroshi Miyata, Makoto Yamasaki, Yukinori Kurokawa, Ryuji Osawa,
Kazuyoshi Takeda, Koji Yoshida, Takuya Tsunoda, Yusuke Nakamura, Masaki Mori,
Yuichiro Doki. Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for
human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric
cancer. Int J Oncol. 2012; 41; 1297-304.
53.
Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F,
Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B,
Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV; IMpower133 Study Group.
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
N Engl J Med. 2018 Dec 6; 379(23); 2220-2229.
54.
Ilya Tsimafeyeu, Evgeny Imyanitov, Larisa Zavalishina, Grigory Raskin, Patrisia
Povilaitite, Nikita Savelov, Ekaterina Kharitonova, Alexey Rumyantsev, Inna Pugach, Yulia
Andreeva, Alexey Petrov, Georgy Frank, Sergei Tjulandin. Agreement between PDL1
immunohistochemistry assays and polymerase chain reaction in non-small cell lung cancer:
CLOVER comparison study. Sci. Rep. 2020; 10; 3928.
100
55.
J Adam, N Le Stang, I Rouquette, A Cazes, C Badoual, H Pinot-Roussel, L Tixier, C Danel,
F Damiola, D Damotte, F Penault-Llorca, S Lantuéjoul. Multicenter harmonization study
for PD-L1 IHC testing in non-small-cell lung cancer. Ann. Oncol. 2018; 29; 953–958.
56.
Fred R Hirsch, Abigail McElhinny, Dave Stanforth, James Ranger-Moore, Malinka Jansson,
Karina Kulangara, William Richardson, Penny Towne, Debra Hanks, Bharathi Vennapusa,
Amita Mistry, Rasika Kalamegham, Steve Averbuch, James Novotny, Eric Rubin, Kenneth
Emancipator, Ian McCaffery, J Andrew Williams, Jill Walker, John Longshore, Ming Sound
Tsao, Keith M Kerr. PD-L1 immunohistochemistry assays for lung cancer: results from
phase 1 of the blueprint PD-L1 IHC assay comparison project. J. Thorac. Oncol. 2017; 12;
208–222.
57.
Qin Huang, Hongyan Wu, Ling Nie, Jiong Shi, Abraham Lebenthal, Jieyu Chen, Qi Sun,
Jun Yang, Lily Huang, Qing Ye. Primary high-grade neuroendocrine carcinoma of the
esophagus: a clinicopathologic and immunohistochemical study of 42 resection cases. Am
J Surg Pathol. 2013; 37; 467–83.
58.
Moshim Kukar, Adrienne Groman, Usha Malhotra, Graham W Warren, Paul Bogner,
Chukwumere E Nwogu, Todd L Demmy, Sai Yendamuri. Small Cell Carcinoma of the
Esophagus: A SEER Database Analysis. Ann Surg Oncol. 2013; 20; 4239-44.
59.
Yun JP, Zhang MF, Hou JH, Tian QH, Fu J, Liang XM, Wu QL, Rong TH. Primary small
cell carcinoma of the esophagus: clinicopathological and immunohistochemical features of
21 cases. BMC Cancer. 2007; 7; 38.
60.
Akinori Egashira, Masaru Morita, Reiko Kumagai, Ken-Ichi Taguchi, Masanobu Ueda,
Shohei Yamaguchi, Manabu Yamamoto, Kazuhito Minami, Yasuharu Ikeda, Yasushi Toh.
Neuroendocrine
carcinoma
of
the
esophagus:
clinicopathological
immunohistochemical features of 14 cases. PLoS ONE. 2017; 12; e0173501.
101
and
61.
Wen Cai, Weiting Ge, Ying Yuan, Kefeng Ding, Yinuo Tan, Dehao Wu, Hanguang Hu. A
10-year population-based study of the differences between NECs and carcinomas of the
esophagus in terms of clinicopathology and survival. J Cancer. 2019; 10; 1520–1527.
62.
Japan Neuroendocrine Tumor Society. Clinical practice guidelines for gastroenteropancreatic
neuroendocrine neoplasms (GEP-NEN) .2019, Kanehara & Co., Ltd, Tokyo (in Japanese)
63.
Ruidi Jiao, Hui Luo, Wenbo Xu, Hong Ge. Immune checkpoint inhibitors in esophageal
squamous cell carcinoma: progress and opportunities. OncoTargets Ther. 2019; 12; 60236032.
64.
Takashi Kojima, Manish A Shah, Kei Muro, Eric Francois, Antoine Adenis, Chih-Hung Hsu,
Toshihiko Doi, Toshikazu Moriwaki, Sung-Bae Kim, Se-Hoon Lee, Jaafar Bennouna, Ken
Kato, Lin Shen, Peter Enzinger, Shu-Kui Qin, Paula Ferreira, Jia Chen, Gustavo Girotto,
Christelle de la Fouchardiere, Helene Senellart, Raed Al-Rajabi, Florian Lordick, Ruixue
Wang, Shailaja Suryawanshi, Pooja Bhagia, S Peter Kang, Jean-Philippe Metges,
KEYNOTE-181 Investigators. Randomized Phase III KEYNOTE-181 Study of
Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. J Clin Oncol.
2020; JCO2001888. doi: 10.1200/JCO.20.01888. Online ahead of print.
65.
Manish A Shah, Takashi Kojima, Daniel Hochhauser, Peter Enzinger, Judith Raimbourg,
Antoine Hollebecque, Florian Lordick, Sung-Bae Kim, Masahiro Tajika, Heung Tae Kim,
A Craig Lockhart, Hendrik-Tobias Arkenau, Farid El-Hajbi, Mukul Gupta, Per Pfeiffer, Qi
Liu, Jared Lunceford, S Peter Kang, Pooja Bhagia, Ken Kato. Efficacy and safety of
pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma
or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study. JAMA
Oncol. 2019; 5; 546-550.
66.
Taisuke Yagi, Yoshifumi Baba, Takatsugu Ishimoto, Masaaki Iwatsuki, Yuji Miyamoto,
102
Naoya Yoshida, Masayuki Watanabe, Hideo Baba. PD-L1 expression, tumor-infiltrating
lymphocytes, and clinical outcome in patients with surgically resected esophageal cancer.
Ann Surg. 2019; 269; 471-478.
67.
Kaiyan Chen, Guoping Cheng, Fanrong Zhang, Nan Zhang, Dan Li, Jiaoyue Jin, Junzhou
Wu, Lisha Ying, Weimin Mao, Dan Su. Prognostic significance of programmed death-1 and
programmed death-ligand 1 expression in patients with esophageal squamous cell
carcinoma. Oncotarget. 2016; 7; 30772-30780.
68.
Akiyuki Wakita, Satoru Motoyama, Hiroshi Nanjo, Yusuke Sato, Kei Yoshino, Tomohiko
Sasaki, Yuta Kawakita, Jiajia Liu, Kazuhiro Imai, Hajime Saito, Yoshihiro Minamiya. PDL1 expression is a prognostic factor in patients with thoracic esophageal cancer treated
without adjuvant chemotherapy. Anticancer Res. 2017; 37; 1433-1441.
69.
Shuhei Ito, Shinji Okano, Masaru Morita, Hiroshi Saeki, Satoshi Tsutsumi, Hiroshi
Tsukihara, Yuichiro Nakashima, Koji Ando, Yu Imamura, Kippei Ohgaki, Eiji Oki,
Hiroyuki Kitao, Koshi Mimori, Yoshihiko Maehara. Expression of PD-L1 and HLA class I
in esophageal squamous cell carcinoma: prognostic factors for patient outcome. Ann Surg
Oncol. 2016; 23; 508-515.
70.
Kosaku Mimura, Leo Yamada, Daisuke Ujiie, Suguru Hayase, Takeshi Tada, Hiroyuki
Hanayama, Aung Kyi Thar Min, Masahiko Shibata, Tomoyuki Momma, Zenichiro Saze,
Shinji Ohki, Koji Kono. Immunotherapy for esophageal squamous cell carcinoma: a review.
Fukushima J Med Sci. 2018; 64; 46-53.
71.
Ryohei Kawabata, Hisashi Wada, Midori Isobe, Takashi Saika, Shuichiro Sato, Akiko
Uenaka, Hiroshi Miyata, Takushi Yasuda, Yuichiro Doki, Yuji Noguchi, Hiromi Kumon,
Kazuhide Tsuji, Keiji Iwatsuki, Hiroshi Shiku, Gerd Ritter, Roger Murphy, Eric Hoffman,
Lloyd J Old, Morito Monden, Eiichi Nakayama. Antibody response against NY‐ESO‐1 in
103
CHP‐NY‐ESO‐1 vaccinated patients. Int J Cancer. 2007; 120; 2178-2184.
72.
H Daiko, T Marafioti, T Fujiwara, Y Shirakawa, T Nakatsura, K Kato, I Puccio, T Hikichi,
S Yoshimura, T Nakagawa, M Furukawa, K Stoeber, M Nagira, N Ide, T Kojima.
Exploratory open-label clinical study to determine the S-588410 cancer peptide vaccineinduced tumor-infiltrating lymphocytes and changes in the tumor microenvironment in
esophageal cancer patients. Cancer Immunol Immunother. 2020; 69; 2247-2257.
73.
K Schumacher, W Haensch, C Röefzaad, P M Schlag. Prognostic significance of activated
CD8(+) T cell infiltrations within esophageal carcinomas. Can Res. 2001; 61; 3932-3936.
74.
Xiao Zheng, Xing Song, Yingjie Shao, Bin Xu, Wenwei Hu, Qi Zhou, Lujun Chen, Dachuan
Zhang, Changping Wu, Jingting Jiang. Prognostic role of tumor-infiltrating lymphocytes in
esophagus cancer: a meta-analysis. Cell Physiol Biochem. 2018; 45; 720-732.
75.
Russell Bonneville, Melanie A Krook, Esko A Kautto, Jharna Miya, Michele R Wing, HuiZi Chen, Julie W Reeser, Lianbo Yu, Sameek Roychowdhury. Landscape of microsatellite
instability across 39 cancer types. JCO Precis Oncol. 2017; 2017; 1-15.
76.
Feng Wang, Dong-Bing Liu, Qi Zhao, Gang Chen, Xin-Ming Liu, Ying-Nan Wang, Hong
Su, Yan-Ru Qin, Yi-Fu He, Qing-Feng Zou, Yan-Hui Liu, You-En Lin, Ze-Xian Liu, JinXin Bei, Rui-Hua Xu. The genomic landscape of small cell carcinoma of the esophagus.
Cell Res. 2018; 28; 771-4.
77.
Scoazec JY, Rindi G. Oesophageal neuroendocrine neoplasms. In WHO Classification of
Tumours Editorial Board eds. World Health Organization classification of tumours.
Digestive system tumours, 5th edn. Lyon: IARC Press, 2019; 56–58.
78.
N Hashimoto, M Tachibana, D K Dhar, H Yoshimura, N Nagasue. Expression of p53 and
RB proteins in squamous cell carcinoma of the esophagus: their relationship with
clinicopathologic characteristics. Ann Surg Oncol. 1999; 6; 489-94.
104
79.
Koichiro Fujimasa, Nobuyuki Ohike, Tomoko Norose, Tomohide Isobe, Kazuo Kikuchi,
Koji Otsuka, Masahiko Murakami, Masafumi Takimoto. Frequent and Specific
Involvement of Changes of the p16-RB Pathway in Esophageal Neuroendocrine Carcinoma.
Anticancer Res. 2019; 39; 1927-1934.
80.
Wang F, Liu DB, Zhao Q, Chen G, Liu XM, Wang YN, Su H, Qin YR, He YF, Zou QF, Liu
YH, Lin YE, Liu ZX, Bei JX, Xu RH. The genomic landscape of small cell carcinoma of
the esophagus. Cell Res. 2018 Jul; 28(7); 771-774.
81.
Chen Q, Fu YY, Yue QN, Wu Q, Tang Y, Wang WY, Wang YS, Jiang LL. Distribution of
PD-L1 expression and its relationship with clinicopathological variables: an audit from
1071 cases of surgically resected non-small cell lung cancer. Int J Clin Exp Pathol. 2019
Mar 1; 12(3); 774-786. eCollection 2019.
82.
Saglam O, Conejo-Garcia J. PD-1/PD-L1 immune checkpoint inhibitors in advanced
cervical cancer. Integr Cancer Sci Ther. 2018; 5(2); 10.15761/ICST.1000272.
83.
Kee Siang Lim, Kosaku Mimura, Ley-Fang Kua, Kensuke Shiraishi, Koji Kono. Implication
of highly cytotoxic natural killer cells for esophageal squamous cell carcinoma treatment.
J Immunother. 2018; 41; 261-273.
84.
Yoshifumi Baba, Daichi Nomoto, Kazuo Okadome, Takatsugu Ishimoto, Masaaki Iwatsuki,
Yuji Miyamoto, Naoya Yoshida, Hideo Baba. Tumor immune microenvironment and
immune checkpoint inhibitors in esophageal squamous cell carcinoma. Cancer Sci. 2020;
111; 3132–3141.
105
略語集
略語：AC+，腺癌成分のみで HER2 陽性； AdenoCa，腺癌成分の有無； Adj, adjuvant
chemotherapy 術補補助化学療法；
Alive，alive with no evidence of disease 無病生存；
AWD，Alive with disease 有病生存； CCRT, concurrent chemoradiotherapy 同時性化学放射
線療法；
CPS, combined positive score ；
chemotherapy 化学療法；
CR, complete response 完 全 奏 功 ；
DOC，dead of other causes 他病死；
病死； Large，大細胞型；
LN，リンパ節；
CT,
DOD，dead of disease 原
Ly，リンパ管侵襲； MANEC，混合腺
神経内分泌癌； MiNEN，mixed neuroendocrine-non-neuroendocrine neoplasm 混合神経内
Mut，変異型パターン；
分泌-非神経内分泌腫瘍；
NAC, neoadjuvant chemotherapy 術
前化学療法； NEC, neuroend ...
論文の公開元へ
